伐地那非治疗阴蒂功能障碍（ED）

睾丸锥体（ED）病变不够举事例来知道适用Vardenafil（拔地那非）来进行疗程对ED口服Sildenafil（西地那非）和Vardenafil（拔地那非）来进行举事例来知道相当实验，决心必须得到无同特质恋的结果。费城-2006年9月20日，深入研究结果发表在《特质快报》上，同时在叙利亚德黑兰才会议的特质医学国际协才会第十二届大才会上发布。这项深入研究不够为契合，因为其资料来自一项关于PDE5（磷酸二脂酶5）消除口服的直接对比流行病学试验，该试验适用PDE5消除口服来疗程ED病变。整个深入研究经过精心设计使得针对每种口服的同特质恋超越成比例。这是一项随机、双盲、复合和直接对比的流行病学试验，适用西地那非和拔地那非疗程患有ED、糖尿病、高血压和/或高血脂的男特质病变，相当了二者的治果。结果揭示在数个中用的有效特质特测试方法上拔地那非取得了统计学意涵上的优势，在产妇满意度和举事例来知道特质的多个风险评估验证里，拔地那非的乏善可陈并不比西地那非差。共计1，057名男特质参与了这项深入研究，他们首先连续四个星期施用一种口服，然后是一个星期时间的缓冲期，接着再继续连续四个星期施用另一种口服。产妇才会被答道这样的难题：“总的来知道，你不够喜欢适用那种口服？”此外还有其他11个有关ED疗程的难题。透过原计划准则来进行比如说有效特质风险评估在分析里也被适用。资料揭示38.9%的产妇举事例来知道适用拔地那非，而34.5%的产妇愿意适用西地那非（26.6%的产妇无举事例来知道特质）。在睾丸新功能，满意度和总体满意度方面，拔地那非显著优于西地那非。在睾丸时抽出硬度，睾丸保持时间，全程保持和睾丸信心方面，拔地那非也有极高比事例的阳特质反应。这项深入研究的合作作者，特质快报的编辑出版Irwin Goldstein 解释知道：“该深入研究表明我们对PDE5消除口服流行病学区分的理解又前行了重要一步，肯定了拔地那非疗程ED的。”以外有三种PDE5消除口服可用于疗程ED，它们分别是西地那非，他曾达那非和拔地那非。根据深入研究者的知道法，所有这三种口服对一定区域内的一些人都乏善可陈出有效特质和耐受特质。来自直接对比的流行病学实验资料（如本项深入研究）不够为稀少，然而这样的深入研究结果才会帮助流行病学牙医对西地那非、拔地那非和他曾达那非加以区分以选择最适合于的口服供个体病病变适用。背景学问：ED：睾丸锥体 Erectile dysfunction, ED是特指不间断没法超越或者保持睾丸以符合。ED比过去用的"阳萎"（Impotence）一词不够确切，因为高血压一词具有一定歧特质的贬义。ED可按其某种程度分为轻、里、重三度，高血压属于重度的ED。70年代后由于睾丸生理和流行病学深入研究的成果，人们了解到固然所致确有可以招致ED，但对大多数男特质来知道，ED与许多性疾病（高血压，糖尿病，心神经性疾病）、口服、脸部及动手术等有关，因为睾丸选择性是腹膜里枢神经松弛，脊柱扩大张，血东流上升和静脉回东流受阻等完整肠道动力学处理过程，在这一处理过程里，任何锥体的致病可以分为： 器质特质ED 血管特质原因：都有任何可能引致腹膜脊柱血东流上升的性疾病，如：脊柱粥样变硬，脊柱挫伤，脊柱陡峭，脊柱分东流及心新功能异常等，或杜绝静脉回东流闭合选择性的白膜、海绵窦内里枢神经上升再继续加的静脉漏。 脑部特质原因：里枢、锥体脑部性疾病或挫伤均可以引致睾丸锥体。 动手术与脸部：大血管动手术、癌根治术、腹才会阴直肠癌根治术等动手术及骨盆骨折、脊柱压缩特质骨折或座骑跨伤，可以招致起有关的血管和脑部挫伤，引致睾丸锥体。 生理强迫症、慢特质病和长期施用某些口服也可以招致睾丸锥体。 本身性疾病：如硬结症（Peyronie's disease）、凸起畸形、导致包皮和包皮驯养炎。 心理特质ED 特指紧张、压力、抑郁、焦虑和夫妻感情不和等自觉所致所引发的睾丸锥体。 混合特质ED 特指自觉所致和器质特质致病合作引致的睾丸锥体。此外，由于器质特质ED仍未得到及时的疗程病变精神上连带，畏惧失败，使ED疗程不够靠拢复杂。国内一组628事例ED病变致病分类的深入研究表明：心理特质占去39%。器质特质为15.8%，混合特质占去45.2%。PDE5消除剂PDE5是腹膜里里枢神经人体内第二信使NO-cGMP的分解酶。PDE5消除剂必须上升cGMP的浓度，增强腹膜里枢神经的舒张作用，并倡导特质器官抑止的睾丸反应。PDE5消除剂类口服对ED疗程具备最广为的有效特质和耐受特质。因此，该类口服被当作口服疗程口服的简介准则。以外，该类口服都有三种：西地那非、拔地那非和他曾达帕非。西地那非在1998年，拔地那非和他帕那非则是在2003年得到世界各地认证。在流行病学适用以及流行病学对应深入研究里辨认出，PDE5消除剂具备良好的耐受特质和有效特质。在基本上ED病变里，流行病学深入研究充分推测上述三种口服的有效特质。 Study shows men with ED for treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON -- September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in ysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors ailable to treat ED: sildenafil, tadalafil and vardenafil, all of which he previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.编辑：bluelove

编辑： Zhu